HHS spurs development of smallpox therapeutic to enhance health security


The US Department of Health and Human Services' (HHS) Biomedical Advanced Research and Development Authority (BARDA) will work with BioFactura, Inc., providing expertise and $9.5 million over two years to develop a monoclonal antibody treatment for smallpox. BARDA has options to support additional work, providing up to a total of $67.4 million over five years.

Content Information

Content Author: 
unknown
Content Source: 
US Department of Health and Human Services (HHS)
Content Type: 
News